.svg)
Tablets and capsules remain the most widely used oral dosage formats, but they come with well-documented limitations. Many drug molecules continue to face poor solubility, low absorption, enzymatic degradation, and inconsistent bioavailability. These formulation challenges are driving the demand for more advanced oral drug delivery system technologies that can improve therapeutic performance without compromising patient convenience.
This shift is accelerating interest in nanotechnology-based oral drug delivery. An approach where nano-scale carriers are engineered to enhance drug solubility, stability, absorption, and controlled release.
Conventional oral drug delivery systems often face a consistent set of challenges: water-soluble APIs, variable gastrointestinal absorption, and first-pass metabolism losses. Industry estimates suggest that nearly 40% of new drug candidates demonstrate poor aqueous solubility, directly affecting therapeutic effectiveness and formulation viability.
Nanotechnology-based oral drug delivery addresses these limitations by engineering drug carriers at the nanometre scale, typically between 1 and 100 nanometres. This significantly increases surface area and improves dissolution behaviour, allowing better absorption and enhanced therapeutic efficiency.
The growing demand for patient-centric therapies is also contributing to adoption. Pharmaceutical companies are increasingly prioritising dosage formats that support
India’s pharmaceutical ecosystem is particularly well positioned for this transition, backed by a strong manufacturing base, proven cost competitiveness, and growth investment in advanced drug delivery technologies.
Nanotechnology in an oral drug delivery system involves the use of nano-scale carriers that improve how APIs are protected, transported, absorbed, and released within the body.
These nano-carriers include
Unlike conventional formulations, nanotechnology-based oral drug delivery systems can improve permeability across biological membranes while protecting sensitive APIs from degradation caused by gastric acid, enzymes, and intestinal conditions.
This enables more engineered and targeted therapeutic delivery across several categories including oncology, CNS therapies, cardiovascular treatments, diabetes management, and nutraceutical applications.
The growing adoption of nanotechnology-based oral drug delivery is driven by one core advantage: the ability to improve therapeutic precision and overall formulation performance.
Nano-scale drug particles dissolve more efficiently because of their larger surface-area-to-volume ratio. This can significantly improve the absorption profile of poorly soluble APIs and reduce variability in patient response.
Nano-enabled oral drug delivery systems can be engineered for sustained, delayed, or site-specific release. This allows manufacturers to maintain drug concentrations within the therapeutic window for longer durations while reducing off-target exposure.
Improved absorption efficiency often enables lower API dosing while maintaining therapeutic efficacy. In some nano-enabled formulations, significant dose reductions may be achievable depending on the molecule and delivery mechanism.
One of the most promising developments is the convergence of nanotechnology with oral thin film pharmaceutical technologies.
Nano-enabled APIs can be incorporated into oral thin films to support
This combination is helping create more patient-centric dosage formats that are fast-dissolving, portable, and easier to administer.
India’s pharmaceutical sector is at an inflection point. The country already contributes nearly 20% of global pharmaceutical production by volume, but the next phase of growth is increasingly focused on complex formulations and innovation-led manufacturing.
This creates significant opportunity in nanotechnology oral drug delivery.
However, key challenges slowing adoption include
Nano-formulations also require highly controlled environments and sophisticated stability management systems, making commercial manufacturing more complex than conventional dosage forms.
India offers several structural advantages
Indian pharmaceutical manufacturers are increasingly investing in advanced oral drug delivery system technologies that combine affordability with formulation sophistication.
As nano-enabled formulations become more complex, pharmaceutical companies are increasingly relying on CDMOs for specialised development and manufacturing support.
Modern CDMOs now provide integrated capabilities across
The growing importance of CDMOs also reflects a broader industry shift toward flexible outsourcing models for advanced oral drug delivery system development.
The future of nanotechnology-based oral drug delivery will be shaped by rising demand for precision medicine, patient-centric therapies, and advanced delivery formats designed to maximise therapeutic efficiency.
Several industry trends are expected to accelerate over the coming years
India is also expected to play a much larger role in global nano-pharma manufacturing as CDMO capabilities continue to mature.
The convergence of nanotechnology with oral thin film pharmaceutical platforms may become one of the most important developments in next-generation oral therapeutics, particularly for therapies requiring enhanced absorption, rapid onset, and improved patient compliance.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
